Early 68 Ga-FAP-2286 PET Imaging

The use of ⁶⁸Ga–labeled inhibitors of fibroblast activation protein (FAP) presents a promising approach for cancer diagnosis. Ga-68-FAP-2286 as one of Pars Isotope’s new products, has successfully completed preclinical and clinical trials, is now in the company’s diagnostic product portfolio, and has the ability to diagnose more than 30 types of cancer.

This radiopharmaceutical remains an attractive option for new research due to its high detection power. Our colleagues recently conducted a study on early PET imaging with this radiopharmaceutical. In this case study, a 55-year-old woman with metastatic adenocarcinoma of the breast and a history of primary tumor resection and multiple recurrent lesions underwent early and late PET imaging with the radiopharmaceutical Ga-68-FAP-2286. Imaging scans were performed at 10 and 60 min intervals after injection.

Imaging results showed that there were 11 local recurrences, one brain metastasis, one lymph node lesion, one lung lesion, and 13 skeletal metastases. Also, SUVmax and TBR (tumor to background ratio) values ​​were higher in imaging 10 minutes after injection than in imaging 60 minutes after injection.

Despite the many advantages of Ga-68-FAP-2286 over other diagnostic radiopharmaceuticals such as FDG and Ga-68-FAP-02,04,46, our study shows for the first time that PET/CT imaging time with this radiopharmaceutical can be reduced to 10 minutes after injection.

This radiopharmaceutical has advantages over FDG, including no fasting and no waiting time after injection. It also provides greater uptake in primary tumors and metastatic lesions, faster clearance from the body, and reduced background in images compared to other FAP peptides.